The interaction of fibrinogen with monocytes was studied. After stimulation with ADP (10 jiM) or thrombin (1 U/ml), plateletfree suspensions of human monocytes bind 1251-fibrinogen with two different affinities in a specific and Ca2+-dependent reaction with saturation at 5.80-7.35 X 1o-7 M of added protein. The binding of fibrinogen to specific receptors on monocytes induces the procoagulant activity of these cells. Thrombasthenic cells or normal monocytes preincubated with a monoclonal antibody to the platelet glycoprotein IUb/IlIa complex (1OE5) do not bind fibrinogen and have no procoagulant activity. Metabolic studies with I35Slmethionine revealed that cultured monocytes actually synthesize a surface antigen precipitated by lOE5 antibody as a major band with 92,000 relative molecular weight. Our data indicate that monocytes express receptors for fibrinogen only in part related to the platelet glycoprotein IIb/Illa complex. Furthermore, the binding of fibrinogen to monocytes enhances the cooperation of these cells in hemostasis.
Introduction
Human monocytes have many different functions in the immune response. These cells mediate the scavenging of tissues and body fluids (1, 2) , humoral cooperation with peripheral lymphocytes (3, 4) and antibody-dependent cellular cytotoxicity (5) . Moreover, monocytes widely interact with the hemostatic system. Procoagulant activity (PCA)' after stimulation with several agents (6-1 1), membrane binding of plasma coagulation factors (12) , association of fibrin to the cell surface (13) (14) (15) , ability to synthesize and secrete fibronectin ( 16) or thrombospondin ( 17) are indications of the important participation of monocytes in coagulation. There have also been reports indicating that the glycoprotein IIb/IIIa complex (GP IIb/IIIa complex), a receptor for fibrinogen on platelets (18) (19) (20) (21) (22) (23) , is also present on normal plasma was discarded and the pelleted erythrocytes and mononuclear cells were resuspended and diluted with an equal volume of cold 0.14 M phosphate buffered-saline (PBS), pH 7.4. 35 ml were layered onto 15 ml of Lymphoprep in 50-ml polypropylene conical tubes and centrifuged at 400 g for 40 min at room temperature. The cells at the interface were carefully removed with sterile plastic pipettes; were washed two times with excess 5 mM PBS-EDTA, centrifuged once at 400 g for 20 min at 4VC, then once at 120 g for 12 min at 4VC to remove further platelet contaminants; a last wash with EDTA-free buffer was also centrifuged at 120 g for 12 min at 4VC. To obtain platelet-free suspensions of monocytes, in addition to adding EDTA to the washing buffer, we removed platelets adhering to monocytes by the method of Pawlowski et al. (31) . Briefly, suspensions of PBMC were incubated twice at 370C for 15 min in autologous serum supplemented with 5 mM EDTA. Cells were then recovered by centrifugation at 400 g for 15 min at room temperature and resuspended in RPMI 1640 medium containing 50 U/ml penicillin, 0.125 ng/ml fungizone, and 50 ,g/ml streptomycin plus 10% autologous serum to give 8 X 106 cells/ml. Autologous serum was prepared by allowing the blood to clot in plastic tubes at 370C for at least 120 min and centrifugation at 3,200 g for 15 min at room temperature. Human monocytes were separated by PBMC as described by Fischer et al. (32) . Briefly, 5 ml of the purified mononuclear cell suspension (8 X 106/ml) were layered on each precoated plate and incubated at 37°C for 60 min in an incubator. At the end of the incubation, the medium, containing mainly lymphocytes, was removed and used for lymphocyte preparations. The plates were rinsed with four to five rapid changes of RPMI 1640 prewarmed to 37°C. 4 ml of Versene were added and after a 15-min incubation at room temperature, 1 ml of autologous serum was added and the loosely adherent monocytes were scraped off with a rubber policeman. Monocytes from several plates were pooled, centrifuged at 400 g for 10 min at 4°C and resuspended in RPMI 1640 containing 10% of autologous serum to give 1.5 X I07 cells/ml. Cells were kept at 4°C until ready to use. The purity of the monocyte preparations obtained in this way was >90%, as assessed by a-naphthyl acetate esterase staining and the viability was >95% as judged by trypan blue exclusion. Strictly aseptic conditions were used to preserve sterility during each step of the cell isolation procedures. With these precautions, the Limulus amebocyte lysate assay for detection ofendotoxin contaminant in monocyte cultures isolated as described above gave <0.1 ng/ml of endotoxin, with 0.1 ng/ ml as lower limit of the method.
Purified monocyte preparations were also obtained from two patients with Glanzmann's thrombasthenia type 1. These patients have been described in previous publications (33, 34) and fulfill all the accepted criteria for diagnosis.
Platelet isolation and labeling. Washed human platelets were prepared by the method of Mustard et al. (35) from freshly collected blood anticoagulated with acid citrate/dextrose. Platelets were counted by phase contrast microscopy and diluted to 4 X 108/ml in Tyrode's albumin buffer pH 7.35. In labeling experiments, washed platelets were suspended in Hepes buffer containing 3.8 mM Hepes, 3.8 mM NaH2PO4, 0.137 M NaCl, 2.7 mM KC1, 1 mM MgCI2 and 0.01% dextrose, pH 7.35. 1 ml ofplatelet suspension (4 X 108/ml) was iodinated by the Iodogen method, as described by Tuszynski et al. (36) .
Electron microscopy studies. Several monocyte preparations were studied by electron microscopy to detect adherent platelets or fragments of platelets surrounding the cell surface. Aliquots (0.3 ml) of monocyte suspensions were adjusted to 0.7-1 X 107/ml in RPMI 1640 containing 10% ofautologous serum. Cells were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.3, and centrifuged at 400 g for 15 min at 4°C. The pellet obtained was stored at 4°C until use.
Protein purification and labeling. Fibrinogen, purified from human plasma by the glycine precipitation method (37) and 90-95% clottable was radiolabeled with 125I by the Iodogen method (38) . Typically, 170
Ag of Iodogen in 170 Mtl of dichloromethane were dried in the bottom of a glass tube; 200 Ml of fibrinogen (5 mg/ml) resuspended in 0.055 M sodium citrate buffer, pH 7.4, were placed in the tube and 700 MCi (7 Ml) of carrier-free sodium ['25I]iodide added. After 20 min of incubation on ice with occasional agitation, the solution was removed from the tube and gel filtered on a Sepharose G-25 coarse column (100 X 2.5 cm) equilibrated with 0.055 M sodium citrate buffer, pH 7.4. Specific activity of 25I-fibrinogen ranged from 4.5 to 8 X l0 cpm/Mg.
Human von Willebrand factor (vWF) was purified as described by De Marco and Shapiro (39) and was radiolabeled with '25I by the Iodogen method. Specific activity of 125I-vWF was 3.2 X l0 cpm/Mg. Human purified fibronectin was a gift from Dr. Cutolo (Rheumatological Center, Genoa University, Genoa, Italy).
'I-Fibrinogen binding to human monocytes. The ability of normal or thrombasthenic monocytes to bind fibrinogen was investigated as follows. In a typical experiment, aliquots (0.2 ml) of monocyte suspension (1.5 X 107/ml) were incubated at room temperature with 1 U/ml thrombin or 10 MM ADP in the presence of 1 mM CaCI2. After I min incubation, 5 U/ml hirudin were added and the mixture incubated at room temperature in the presence of'251I-fibrinogen (6 X 1o-8 M). No differences were observed when the incubation of monocytes with ADP was prolonged to 15 min at room temperature. In all experiments, the final volume was adjusted to 0.35 ml with RPMI 1640. Similar incubations were also performed at 4VC or at 370C. The amount of I-fibrinogen bound to monocytes was measured at selected time intervals between 1 and 60 min. At the end of each interval, after gentle resuspension, 0.3-ml portions were layered onto 50 MA of silicone oil in 0.5 ml micro-Eppendorf tubes and free and monocyte-bound fibrinogen were separated by centrifugation at 12,000 g for 2 min at room temperature in an Eppendorf 5414 centrifuge. Specific binding was calculated by subtracting from the total the amount of fibrinogen bound in the presence of a 50-fold excess of unlabeled fibrinogen added to the monocyte suspension at the start of the incubation (nonspecific binding). Nonspecific binding varied from 20 to 30% of the total. When the competitive inhibition by fibrinogen, vWF or fibronectin oflabeled fibrinogen binding to monocytes was evaluated, 7.3 X l0-7 M of fibrinogen or 250 Mug/ml of vWF or fibronectin were incubated with monocytes before the addition of concentrations of 2'21-fibrinogen ranging from 0.14 to 1.47
To define the role of Ca2' ions in fibrinogen binding to monocytes, aliquots (0.2 ml) of monocyte suspension were preincubated with 10 mM EDTA for 1 min before the addition of the stimulants. For doseresponse studies, 0.2-ml aliquots of monocyte suspension were incubated in a final volume of 0.35 ml with 1 U/ml thrombin or 10 MM ADP in the presence of 1 mM CaCI2. After the addition of 5 U/ml hirudin, increasing concentrations (0.03-8.80 X 10-7 M) of 125I-fibrinogen were added and fibrinogen binding to monocytes was determined 15 min later as described above. Radioactivity in pellet and supernatant were measured in a gammacounter (model 1260, LKB, Bromma, Sweden).
'25I-vWF binding to monocytes. Aliquots (0.2 ml) of monocyte suspension were stimulated with thrombin (1 U/ml) for 1 min at room temperature in the presence of 1 mM CaCI2. After the addition of 5 U/ml hirudin, the mixture was incubated with various concentrations (2- (36) . After three washes in Hepes buffer pH 7.35, the pellet was resuspended for 30 min at 4VC in 1 ml of lysis buffer containing 1% Nonidet P-40, 0.5% Triton X-100, 0.05 M Tris-HCl, 0.15 M NaCl, 0.1I% BSA, 0.001 M PMSF, pH 8.3. At the end ofthe incubation the lysate was centrifuged at 12,000 g for 10 min and the supernatant was collected. Immunoprecipitation studies were carried out as described previously (42) with the following modifications. Aliquots ofthe platelet or monocyte lysate were incubated with 70 ,g/ml of lOE5 antibody for 18 h at 4VC. 25 Ml of protein A Sepharose CL 4B (0.2 g/ml) were then added and the incubation continued for additional 6 h at 4VC. After extensive washing with 0.14 M PBS, pH 7.4, the immunoprecipitate was solubilized in 3% SDS, reduced with 0.2 M DTT, and boiled for 5 min at 100IC to release the bound antigen and antibody. The supernatant obtained after centrifugation at 12,000 g for 5 min was electrophoresed on a 7.5% SDS polyacrylamide gel, as described by Laemmli (43) . Comparative molecular weight standards run with each sample were myosin, 200,000 relative mol wt; f3-galactosidase, 116,000 relative mol wt; phosphorylase B, 92,500 relative mol wt; BSA, 66,200 relative mol wt; and ovalbumin, 45,000 relative mol wt. The gels were fixed, stained with Coomassie Brilliant Blue, destained, dried and exposed for autoradiography between a x-ray film (3M Corp., St. Paul, MN) and an intensifying screen (Cronex, E. I. DuPont de Nemours, Wilmington, DE) for 7 d at -70°C.
Metabolic labeling of monocytes. The following experiments were carried out to determine whether the monocyte surface component involved in fibrinogen binding was synthesized during active cell metabolism. Human monocytes were isolated as described above under strict sterility and resuspended at the concentration of 6 X 106/ml in methionine-free minimal essential medium supplemented with 1% L-glutamine, 100 ,ug/ml streptomycin, 100 U/ml penicillin, and 10%o autologous serum (prepared after extensive dialysis against methionine-free minimal essential medium). 400 MCi/ml of [35S]methionine was then added and the cells were cultured at 37°C in a 5% CO2 humidified incubator for 12 h. At the end ofthe incubation, the cells were harvested, washed three times with 0.14 M PBS pH 7.4 and resuspended in 0.5 ml of lysis buffer for 30 min at 4°C, as described above. Immunoprecipitation studies of monocytes pulse-labeled with [35S]methionine were performed with lOE5 antibody as described in the preceding paragraph.
PCA induced by monocytes. Monocyte PCA has been evaluated as described by Kornberg et al. (44) . Suspensions of normal or thrombasthenic monocytes, stimulated to induce fibrinogen binding, were tested for their ability to shorten the clotting time of normal human plasma in a one-stage plasma recalcification time test. Aliquots (0.2 ml) of normal or thrombasthenic monocytes (1.5 X 107/ml) resuspended in RPMI 1640 without serum were incubated with 10 MM ADP in the presence of 1 mM CaCl2. At the end ofthe incubation, 0.1-ml aliquots ofthe mixture were transferred into glass tubes and incubated at 37°C for 1 min with 0.1 ml of plasma obtained from 10 normal donors. 0.1 ml of 0.025 M CaCl2 was then added and the clotting time read.
In some experiments, the ability of ADP-stimulated normal monocytes to shorten the recalcification time of plasmas deficient in various coagulation factors was evaluated. Factor V-, VII-, IX-, X-, and XIIdeficient plasmas were tested with various monocyte preparations. To explore whether soluble factors released by monocytes were involved in the expression ofPCA, suspensions ofADP-stimulated normal monocytes were centrifuged at 12,000 g for 15 min at room temperature. 0.1 ml of the supernatant was tested for its ability to shorten the normal human plasma recalcification time. Control experiments were performed with unstimulated monocytes (1.5 X 107/ml), with unstimulated or ADPstimulated lymphocytes (1.5 X 107/ml), human platelets (4 X 108/ml) or RPMI 1640. Units of PCA were determined by comparison of the plasma clotting time induced by serial dilutions of a standard human brain thromboplastin. A clotting time of22 s (dilution 1:64) was arbitrarily designated as equivalent to 100 U of PCA.
Inhibition of 25I-fibrinogen binding and PCA of monocytes. 20 ,ug/ml of lOE5 antibody were incubated with thrombin (1 U/ml)-or ADP (10 MM)-stimulated monocyte suspensions at room temperature.
After 5 min '25I-fibrinogen (0.03-8.80 X 10-7 M) was added and the extent of fibrinogen binding assayed as described above. Inhibition of monocyte PCA by IOES antibody was studied by incubating 0.3 ml of monocyte suspensions at room temperature for 5 min with 20 Mg/ml of lOE5 antibody. ADP (10 ,M) was then added, in the presence of CaCl2 (1 mM), and the mixture incubated at room temperature for an additional 10 min. PCA generation of these monocytes treated with lOES antibody was assessed as described above.
Protein concentration. Protein concentration was calculated from the absorbance at 280 nm, using extinction coefficients of 1.51 for fibrinogen, 1 .97 for fibronectin, 1.4 for lOE5 antibody, and 1.23 for vWF.
Analysis ofdata. To calculate the number of fibrinogen and lOE5 antibody binding sites on monocytes and the relative dissociation constants (Kd), the value of specific binding was plotted by the method of Scatchard (45) and analyzed by the method ofFeldman (46) . Competitive inhibition by fibrinogen, fibronectin or vWF of '25I-fibrinogen binding to monocytes was calculated from the Lineweaver-Burk double reciprocal plot (47) .
Results
Purity of the monocyte suspension. Several experiments were carried out to evaluate whether or not the monocyte preparations were free of platelet contamination. First, aliquots of washed normal autologous platelets (4 X 108/ml) labeled with 1251 were added to the freshly collected blood. At the end of the cell isolation procedures, <0.1% ofthe platelet-associated radioactivity was found in the final monocyte suspension. Second, to investigate the effects of low levels of platelet contaminant on the monocyte response to fibrinogen, we added aliquots of washed platelets in the monocyte preparation in a ratio of 5:100 platelets/ monocytes. Under these conditions, the interaction of monocytes with fibrinogen did not differ from that of controls without platelets (not shown). Furthermore, aliquots of normal platelets were added to the whole blood of a patient with Glanzmann's thrombasthenia. The lack of '251-fibrinogen interaction with suspensions ofthrombasthenic monocytes further confirmed that all normal platelets exogenously added had been removed during the cell washing procedures. Monocytes were also characterized morphologically. In phase-contrast microscopy there were no free platelets in the monocyte suspensions prepared as described above. Finally, electron microscopy provided evidence that there were neither intact nor disrupted platelets nor fragments of membranes adhering to the monocyte surface (Fig. 1 (Fig. 2) . Preincubation of stimulated monocytes with a 50-fold excess of unlabeled fibrinogen resulted in 70 to 80% inhibition of 1251-fibrinogen binding to monocytes, while excess ovalbumin or intact IgG had no effect. Inhibition of fibrinogen binding by 70 to 80% was also achieved by preincubation of the cell suspension with 10 mM EDTA. The addition of a 50-fold excess of unlabeled fibrinogen at equilibrium induced displacement of >60% of the radioligand bound (Fig. 2) .
The rate of fibrinogen binding in the incubation mixture was found to be directly related to the concentration of monocytes (0.5-2 X 107/ml) and it was optimal when 1. (Fig. 4) . In contrast, '251-IOE5 antibody binding to thrombasthenic monocytes was insignificant (Fig. 4) . Thrombasthenic monocytes were subsequently tested for their ability to bind fibrinogen. After stimulation with ADP or thrombin there was no labeled fibrinogen binding to thrombasthenic cells (Fig. 5) . In addition, preincubation ofnormal stimulated monocytes with 20 pg/ml of IOE5 antibody completely suppressed 1231-fibrinogen specific binding (Fig. 5) . The fibrinogen receptor on the surface ofnormal monocytes was characterized by immunoprecipitation studies with lOE5 antibody. The antigen precipitated in the complex after interaction between lOE5 antibody and normal iodinated platelet or monocyte lysate was identified by SDS polyacrylamide gel electrophoresis followed by autoradiography. Normal reduced platelets treated with lOE5 antibody revealed two major radioactive bands, with 116,000 relative mol wt and 110,000 relative mol wt, in agreement with previous observations (40 (45) and analyzed by the method of Feldman (46 monocytes. Lineweaver-Burk double reciprocal plots of these data revealed that cold fibrinogen competitively inhibited labeled fibrinogen binding, while fibronectin or vWF did not interfere (Fig. 7) . Furthermore, the direct interaction of '25I-vWF with thrombin-stimulated monocytes showed a non-specific and unsaturable association of the labeled protein (not shown). PCA expressed by human monocytes. The binding of fibrinogen to normal monocytes was related to the capacity of these cells to generate procoagulant material. Suspensions of normal monocytes stimulated with ADP to induce fibrinogen binding consistently shortened the normal human plasma recalcification time from that with unstimulated cells (Table I) . Supernatants of stimulated monocytes, lymphocytes or platelets under the same experimental conditions did not have PCA. That fibrinogen binding to specific receptors on stimulated monocytes is directly associated with the PCA generation was further confirmed. In fact, suspensions of stimulated thrombasthenic monocytes or normal monocytes preincubated with lOES antibody at a concentration which totally blocks fibrinogen binding (20 tg/ml) had no PCA (Table I) . ADP-stimulated normal monocytes equally shortened the recalcification times of Factor VII-, IX-, and XII-deficient plasmas. In contrast, cell PCA was abolished when plasma deficient in Factors V or X were tested. This sug- (3) 27.5±9.5 Factor XII-deficient plasma (3) 21.5±4.5 Factor IX-deficient plasma (3) 40.5±4.5 Factor X-deficient plasma (3) 4.0±2.5 Factor V-deficient plasma (3) 5.0±1.0 with thrombin (1 U/ml) were incubated with '25I-fibr trations from 0.15 to 1.47 X 10-' M) in the presence of cold fibrinogen or 250 ug/ml of vWF or fibronecti assay was performed as described in Fig. 2 Normal or thrombasthenic monocytes (1.5 X 107/ml) with ADP (10 MM) for 10 min at room temperature i mM CaC2. 0.1 ml of the mixture was then incubat 0.1 ml of normal plasma. At the end of 1 min incubi 0.025 M CaCl2 was added and the recalcification timi antiplatelet GP IIb/IIIa complex monoclonal antibod for 3 min at room temperature with monocytes befo tion. Lymphocytes (1.5 X 107/ml) or platelets (4 X 10 for their ability to generate PCA under the experimer described above. The data are means±SEM. Taken together, these observations, plus the fact that the number of fibrinogen binding sites on monocytes is different from the number of sites on platelets (18, 19, (21) (22) (23) suggest that there are important differences between the receptor for fibrinogen on monocytes and the platelet GP HIb/IIIa complex. It appears even more unlikely that undetectable platelet contamination thus was responsible for our findings. Moreover, we suggest that these important differences might explain the discrepancies in the literature about the existence of the GP Ilb/ HIla complex on monocytes (24-28). In fact, all previous studies were based only on the different reactivity of antiplatelet antibodies with monocytes. The differences between the fibrinogen receptor on monocytes and the platelet GP Ilb/IIIa complex make it possible that only a few epitopes of these two antigens are identical. Consequently, not all antiplatelet antibodies need necessarily react with monocytes. For this reason, polyclonal antibodies such as those used by Clemetson et al. (27) and by Levene and Rabellino (28) , because their specificity is lower than that of monoclonal antibodies used by others (24, 25, 53) , are less able to identify a monocyte surface component that is similar to but not identical with the platelet GP IIb/IIIa complex. We affirm that some surface antigen, at least in part functionally related to the platelet GP IIb/IIIa complex, therefore, is required for fibrinogen binding to monocytes.
The concept ofa direct interaction offibrinogen with monocytes appears to be further inforced by the recent observation that mouse peritoneal macrophages specifically bind fibrinogen degradation products (54) . Receptors for the D-domain of fibrinogen, only in part functionally related to the platelet GP HIb/IlIa complex have been described on the surface of these cells (54) . The binding of fibrinogen to stimulated platelets is required for aggregation (18-23) and we have shown that the binding of fibrinogen to monocytes greatly enhances the PCA of these cells. In fact, neither normal monocytes preincubated with lOE5 antibody nor thrombasthenic cells bound fibrinogen and had no PCA. Monocyte PCA can be distinguished by its expression after a very short incubation with a particular stimulus (ADP) and by its requirements for Factors X and V. Moreover, monocyte PCA could not be detected in the supernatants of ADP-stimulated cells. Taken together, these observations suggest that under our experimental conditions, rather than being a thromboplastin-like material (6-10), monocyte PCA is membrane-bound and completely independent of the extrinsic or intrinsic coagulation pathway. Therefore the binding of fibrinogen to specific receptors on monocytes appears to be a membrane signal triggering an enzyme-like activity that induces rapid deposition of fibrin on the cell surface.
In conclusion, our data suggest that several stimuli and multiple interactions regulate the PCA expressed by monocytes. Moreover, Glanzmann's thrombasthenia appears to be a congenital disorder with several defects of the hemostatic process. The findings described here, while they demonstrate a specific interaction between monocytes and fibrinogen, also emphasize the concept that coagulation and inflammation are interdependent and closely related processes.
